Translate

Thursday, September 21, 2017

thumbnail

WVE WAVE Life Sciences Ltd. gains 23% Sep 21, 2017

WAVE Life Sciences Ltd., a preclinical biopharmaceutical company, designs, develops, and commercializes nucleic acid therapeutic candidates. The company is developing nucleic acid therapeutics that target genetic defects to either reduce the expression of disease-promoting proteins or transform the production of dysfunctional mutant proteins into the production of functional proteins. Its advanced therapeutic programs are in Huntington's disease, Duchenne muscular dystrophy (DMD), and inflammatory bowel disease (IBD). In Huntington's disease, it has programs targeting HTT SNP-1 and HTT SNP-2; in DMD, targeting Exon 51; and in IBD, targeting SMAD7. The company also has product candidates in its programs targeting HTT SNP-1 and Exon 51. In addition, it has late-stage discovery programs in epidermolysis bullosa simplex, targeting KRT14 SNP-1 and KRT14 SNP-2, as well as in DMD, focuses on an additional DMD target, AcRIIb. The company has a research, license, and option agreement with Pfizer Inc. for the discovery, development, and commercialization of stereopure oligonucleotide therapeutics. WAVE Life Sciences Ltd. was founded in 2012 and is based in Cambridge, Massachusetts. http://www.priceseries.com/trade/WVE-WAVE-Life-Sciences-Ltd-stock-gains-23-percent-a-Trade-Record-by-priceSeries-2017082520170921.html

Subscribe by Email

Follow Updates Articles from This Blog via Email

No Comments

TradeVisor Product Review

Review I II III IV

Blog Archive